CLEC14A

Across TCGA pan-cancer cohorts, CLEC14A Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CLEC14A data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CLEC14A Mutation is associated with better overall survival. In most high-consensus cancer types, elevated CLEC14A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM, LGG, and LUAD are the cancer types where CLEC14A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.991	0.862	.013	13	view →
LGG	OS	Median	All	0.175	0.834	<.001	12	view →
LUAD	DFS	Median	All	0.454	0.772	.006	10	view →
LIHC	OS	Median	All	0.355	0.779	<.001	9	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
GBM	DFS	Median	All	0.091	0.244	.048	3	view →
BLCA	OS	Median	III,IV	0.196	0.579	.032	3	view →
KIRP	OS	Median	All	0.248	0.705	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CLEC14A–SKCM (OS)

Open the SKCM breakdown →